Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron …
WEB4 days ago · Side effects can be reported to EudraVigilance or directly to BioNTech using email [email protected], telephone +49 6131 9084 0, or via the website www.biontech.de
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron …
WEB4 days ago · NEW YORK & MAINZ, Germany, September 20, 2024--Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use ...
BioNTech SE (BNTX) Latest Stock News & Headlines - Yahoo …
WEBGet the latest BioNTech SE (BNTX) stock news and headlines to help you in your trading and investing decisions.
Newsroom - BioNTech
WEBWelcome to the BioNTech Newsroom. In this section you can find a variety of media materials and useful information to download. Media Downloads. Conference "Working Together to Promote Vaccine Equity for Africa", December 18, 2023. Africa Vaccine Equity Conference 1. Africa Vaccine Equity Conference 2. Africa Vaccine Equity Conference 3.
Pfizer-BioNTech COVID-19 Vaccine COMIRNATY® Receives Full …
WEBAug 23, 2021 · NEW YORK & MAINZ, Germany-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for COMIRNATY ® (COVID-19 Vaccine, mRNA) to prevent COVID-19 in individuals 16 years of age and older.
Pfizer and BioNTech Confirm High Efficacy and No Serious Safety ...
WEBApr 1, 2021 · Analysis of 927 confirmed symptomatic cases of COVID-19 demonstrates BNT162b2 is highly effective with 91.3% vaccine efficacy observed against COVID-19, measured seven days through up to six months after the second dose. Vaccine was 100% effective in preventing severe disease as defined by the U.S. Centers for Disease Control and Prevention and ...
Pfizer and BioNTech Announce Positive Topline Data for mRNA …
WEBOct 26, 2023 · NEW YORK & MAINZ, GERMANY-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive topline results from a Phase 1/2 study (NCT05596734) evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age.
US FDA authorizes Pfizer-BioNTech and Moderna's updated …
WEBSept 11 (Reuters) - The U.S. Food and Drug Administration (FDA) on Monday authorized updated COVID-19 vaccines from Pfizer (PFE.N) /BioNTech (22UAy.DE) and Moderna (MRNA.O) that target a recently...
BioNTech raised to buy at Jefferies on new cancer drug - MSN
WEBBioNTech (NASDAQ:BNTX) shares traded higher on Tuesday after Jefferies upgraded the German COVID-19 vaccine maker to Buy from Hold, citing the potential of a new cancer drug it is developing with ...
Jefferies upgrades BioNTech SE (BNTX) to a Buy - Markets Insider
WEBSep. 16, 2024, 11:35 PM. Jefferies analyst Akash Tewari upgraded BioNTech SE (BNTX – Research Report) to a Buy today and set a price target of $150.00. The company’s shares closed yesterday at ...